Skip to main content
US EQUITIES AFTER-HOURS CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
MA

MAZEStockMaze Therapeutics Inc.

Nasdaq Global Market · Healthcare · US

$32.43 last close 2026-11-19
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment MAZE's does — no target price to set, unlike a price alert.

Sharia status
NOT DETERMINED
Our own screen rated every one of the seven published methodologies and none passed, while our secondary compliance provider rates it compliant — we will not publish either as a verdict
0 of 7 pass our own screen — all 7 agree here
HTR non-permissible income 7.03%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure2 of 5 timeframes bullish · 43.5% aligned
VWAPPrice below VWAP ($33.17)
VolumeRelative volume 6.2× the 20-day average
Momentum10-day rate of change -2.2%

Maze Therapeutics Inc. (MAZE) was screened and our screen declined to rate it, so we publish no verdict, per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Price target
$62.46
+92.6% · 13 analysts
Institutional own.
111.8% *
of shares
Momentum (10d)
-2.2%
rate of change
SMC grade
D · 43
43.5% aligned
7.03%
Non-permissible income — HTR, from filings (2025-12-31)
D · 43
SMC grade — 43.5% timeframe alignment
-2.2%
Rate of change (10d)
$62.46
Price target (+92.6%) · 13 analysts
111.8%
Institutional ownership *

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $1.8B as of 2026-11-18. At the 2026-11-19 close it is about $1.7B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 3.4% (3.3% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 22.5% (21.7% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail from an earlier screen 2 of 2 ratios pass

This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.

RatioValueThresholdResult
Interest-bearing debt 3.32% 30.00% Pass(26.7pp buffer)
Interest-bearing investments 21.74% 30.00% Pass(8.3pp buffer)
Usmani Fail 2 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 11.66% 33.00% Pass(21.3pp buffer)
Interest-bearing investments 76.38% 33.00% Fail(43.4pp over)
Non-liquid assets 23.62% at least 20.00% Pass(3.6pp above the floor)
MSCI Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 11.66% 33.33% Pass(21.7pp buffer)
Cash + interest-bearing securities 76.38% 33.33% Fail(43.1pp over)
FTSE Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 7.65% 33.33% Pass(25.7pp buffer)
Cash + interest-bearing securities 76.38% 33.33% Fail(43.1pp over)
Dow Jones Islamic Market Fail from an earlier screen 2 of 2 ratios pass

This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: accounts receivable, non-permissible income not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 4.39% 33.00% Pass(28.6pp buffer)
Cash + interest-bearing securities 28.77% 33.00% Pass(4.2pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)nonliquid assets ratio · floor 3.6pts
Usmani (% of total assets)debt ratio 21.3pts
MSCI Islamic Index (% of total assets)debt ratio 21.7pts
Usmani (% of total assets)investments ratio 43.4pts
MSCI Islamic Index (% of total assets)cash and interest ratio 43.1pts
FTSE Shariah Global Equity Index Series (% of total assets)cash and interest ratio 43.1pts

The numbers the ratios are built from

Read from MAZE's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $39.1M 2026-09-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $390.7M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, MarketableSecuritiesCurrent
Total assetsBalance sheet total $511.6M 2026-09-30 Assets
Market capDenominator for AAOIFI $1.8B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series not measured — —
24-month average market capDenominator for Dow Jones Islamic Market $1.3B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $11.8M 2025-12-31 InterestAndOtherIncome

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-09, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-03-25, period ended 2025-12-31. Screened 2026-11-18.

  • Total assets$511.6M
    Assets · period ended 2026-09-30 · 10-Q filed 2026-11-09
  • Interest-bearing debt$39.1M
    LongTermDebtNoncurrent $39.1M · period ended 2026-09-30 · 10-Q filed 2026-11-09
    LongTermDebtCurrent $0 · period ended 2026-09-30 · 10-Q filed 2026-11-09
  • Cash and interest-bearing securities$390.7M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents $155.2M · period ended 2026-09-30 · 10-Q filed 2026-11-09
    MarketableSecuritiesCurrent $235.5M · period ended 2026-09-30 · 10-Q filed 2026-11-09
  • Interest income (non-permissible)$11.8M
    InterestAndOtherIncome · period ended 2025-12-31 · 10-K filed 2026-03-25
  • Market cap$1.8B
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-18 · not a filing figure, so no link

6 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for MAZE. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for MAZE has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B $520.66-2.94%
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold MAZE

8 of the 277 funds whose filed holdings we currently hold own MAZE shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns MAZE.

You may already own it

Widely held U.S. index funds. If you own one, you own MAZE through it. None of them is a Shariah fund; the last column is our look-through of each.

FundMAZE in fundFund compliant by weight
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00% 54%
SCHB Schwab U.S. Broad Market ETF 0.00% 53%
Other funds
FundMAZE in fundFund compliant by weight
JGLYX JPMorgan Small Cap Growth Fund 0.48% 47%
JESIX Small Cap Index Trust 0.03% 31%
TISBX Nuveen Small Cap Blend Index Fund 0.03% 31%
VEMPX VANGUARD EXTENDED MARKET INDEX FUND 0.01% 42%
JAFFX Total Stock Market Index Trust 0.00% 52%

Sorted by MAZE’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names MAZE once, so a bond is not counted as the shares; 1 more fund name MAZE in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding MAZE
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $44M 0.0% 2026-09-30
Jefferies Jefferies Financial Group $2M 0.0% 2026-09-30
Israel Englander Millennium Management $1M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

51.8344.4737.1129.7522.392025-11-202026-05-222026-11-19

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
27.84
S2
29.40
S1
30.30
PIVOT
31.86
R1
32.76
R2
34.32
R3
35.22

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
20.70 – 31.40
±20.54% from 26.05, made 2026-09-26 · resolves 2026-10-03
SELL
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

BUY
19 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesSTRONG BUY
8 buy · 0 neutral · 4 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)51.50NEUTRAL
Stochastic %K (14)34.99NEUTRAL
CCI (20)-45.91NEUTRAL
Williams %R (14)-65.01NEUTRAL
MACD (12,26,9)-0.42SELL
ROC (10)-0.31SELL
Momentum (10)-0.10SELL
EMA (10)33.26SELL
SMA (10)34.21SELL
EMA (20)32.66SELL
SMA (20)32.98SELL
EMA (30)31.82BUY
SMA (30)31.63BUY
EMA (50)30.63BUY
SMA (50)29.25BUY
EMA (100)29.87BUY
SMA (100)28.83BUY
EMA (200)32.34BUY
SMA (200)31.09BUY

About Maze Therapeutics Inc.

Healthcare · Biotechnology

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

mazetx.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 64
⏰ 4H BEARISH 38
🕐 1H BEARISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-2.2%
Rate of change (10d)
6.2×
Volume vs its 20-day average
1.02
MACD (no fresh cross)
$32.16
Volume POC (today)
$31.58 – $32.47
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.